Hexyl aminolevulinate hydrochloride, sold under the brand names Cysview and Hexvix, is a pharmaceutical imaging agent that lights up under blue light during a blue light cystoscopy. It is used to help detect non-muscle invasive bladder cancer (NMIBC), in particular papillary and carcinoma in situ (CIS). It made by Photocure ASA, a Norwegian pharmaceutical company. November 10, 2010 - Nature (journal) published an article claiming that Photodynamic diagnosis (PDD) can improve surgical outcome on bladder URL Bladder cancer: Photodynamic diagnosis can improve surgical outcome Nature Reviews Urology 7, 598-599 (November 2010) | In 2016, the American Urological Association (AUA) made the following statement with respect to NMIBC: "In a patient with a history of NMIBC with normal cystoscopy and positive cytology, a clinician should consider prostatic urethral biopsies and upper tract imaging, as well as enhanced cystoscopic techniques (blue light cystoscopy, when available), ureteroscopy, or random bladder biopsies. (Expert Opinion)" "In a patient with NMIBC, a clinician should offer blue light cystoscopy at the time of TURBT, if available, to increase detection and decrease recurrence. (Moderate Recommendation; Evidence Strength: Grade B)." 
Hexyl aminolevulinate hydrochloride, sold under the brand names Cysview and Hexvix, is an imaging agent that lights up under blue light during a blue light cystoscopy. It is used to help detect non-muscle invasive bladder cancer (NMIBC), in particular papillary and carcinoma in situ (CIS). In 2016, the American Urological Association (AUA) made the following statement with respect to NMIBC: "In a patient with a history of NMIBC with normal cystoscopy and positive cytology, a clinician should consider prostatic urethral biopsies and upper tract imaging, as well as enhanced cystoscopic techniques (blue light cystoscopy, when available), ureteroscopy, or random bladder biopsies. (Expert Opinion)" "In a patient with NMIBC, a clinician should offer blue light cystoscopy at the time of TURBT, if available, to increase detection and decrease recurrence. (Moderate Recommendation; Evidence Strength: Grade B)." It made by Photocure ASA, a Norwegian pharmaceutical company.
R
a pharmaceutical
an
D
It made by Photocure ASA, a Norwegian pharmaceutical company.
D
November 10, 2010 - Nature (journal) published an article claiming that Photodynamic diagnosis (PDD) can improve surgical outcome on bladder URL Bladder cancer: Photodynamic diagnosis can improve surgical outcome Nature Reviews Urology 7, 598-599 (November 2010) |
A
It made by Photocure ASA, a Norwegian pharmaceutical company.